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Introduction
RA is a common systemic autoimmune disease with a
prevalence of about 1% worldwide. Although the etiology
of the disease is still unknown, several risk factors have
been identified. Like many autoimmune diseases, RA
occurs more frequently in women than in men (3:1 ratio),
suggesting a role for sex hormones. Genetic studies have
demonstrated that a genetic predisposition resides in the
HLA-DR locus. There is also evidence that environmental
factors, such as infectious agents, oral contraceptives and
smoking, may play a role [1].
RA is characterized by inflammation of the synovial mem-
brane of diarthrodial joints. Early indications of RA are
swelling and pain of the proximal interphalangeal and
metacarpophalangeal joints. Later, the larger joints
become affected, especially those of the knee, elbow and
ankle. Large numbers of activated leukocytes infiltrate the
synovial membrane, causing hyperplasia and inflammation,
which in most cases leads to progressive destruction of
cartilage and bone. Since RA is a systemic autoimmune
disease, other parts/organs of the body may become
affected at a later stage. An example of this is the forma-
tion of rheumatoid noduli. Peak onset typically occurs in
the fourth and fifth decades of life.
With more sophisticated types of therapy becoming avail-
able, it is becoming more important to diagnose RA at an
early stage of the disease, so that earlier treatment can be
applied and major damage of joint tissue can be prevented.
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It is during the first period of the disease, when not all clin-
ical parameters are manifest, that a specific and sensitive
serological test is needed. Even more helpful would be the
serological test being able to predict, in an early phase of
RA, the erosive or nonerosive progression of the disease.
Over the past 25 years, many autoantibody activities in
RA have been described. This review summarizes the
most relevant, and attempts to discuss their specificity
and possible diagnostic and prognostic value. We shall
distinguish between RA-associated antibodies, which are
present in RA but also in other diseases, and RA-specific
autoantibodies, which appear to be exclusively present in
RA. It is, of course, the category of RA-specific antibodies
that is most relevant for the clinician.
Autoantibodies associated with RA
Rheumatoid factor
The so-called ‘rheumatoid factor’ (RF) was first described
about 75 years ago; since then a vast amount of work has
been performed on the incidence, nature and specificity of
RF (reviewed in [2]). The RF antibody is present in about
75% of RA patients, but its specificity is limited since RF
is also found in patients with other autoimmune diseases
(e.g. Sjögren’s syndrome), infectious diseases (e.g. hepati-
tis, tuberculosis), and to a certain extent in the healthy
population (3–5%) and healthy elderly individuals
(10–30%). Despite its relatively low specificity, the pres-
ence of RF is widely used as a diagnostic marker for RA.
RFs are antibodies directed to the crystallizable fragment
of IgG molecules. They are found in every immunoglobulin
subclass (IgE, IgM, IgA and IgG). IgG RF has a self-
binding capacity that can result in the formation of very
large immune complexes, which are able to (further) acti-
vate the immune system (reviewed in [3]). It is not clear
whether RF is directly related to the symptoms of RA,
although RF is found significantly more often in cases of
aggressive joint inflammation. In those cases, RF titers are
linearly related with the severity of inflammation. The clini-
cal relevance of RF has been reviewed frequently (see, for
example, [3,4]). Since the presence of RF is one of the
American College of Rheumatology criteria for RA, the
test is performed on a routine basis in most clinical labora-
tories. Some reports mention raised IgA-RF levels as a
parameter for disease activity [5,6]. A combined routine
determination of IgM-RF, IgG-RF and IgA-RF is recom-
mended for an improved sensitivity, for diagnostic speci-
ficity and for predictive value [7,8].
Anti-RA33 antibodies
Hassfeld et al. [9] described a 33 kDa antigen recognized
by sera from RA patients on immunoblots from soluble
nuclear extracts of HeLa cells. The antigen, referred to as
RA33, was recognized by 36% of the RA sera and by only
1% of the normal sera. Characterization of RA33 revealed
that RA33 is identical to the A2 protein of the hetero-
geneous nuclear ribonucleoprotein complex [10]. Hetero-
geneous nuclear ribonucleoproteins are large nuclear
structures present in every eukaryotic cell composed of
long stretches of heterogeneous nuclear RNA associated
with about 30 different proteins, with molecular weights
varying between 34 and 120 kDa. The most abundant pro-
teins in the heterogeneous nuclear ribonucleoprotein com-
plexes, the so-called ‘core’ proteins, are named A1, A2,
B1, B2, C1 and C2.
It has been suggested that RA33 is a marker for early
arthritis [11]. However, the autoantibodies to RA33/A2
protein are not exclusively found in RA patients. They are
also present in systemic lupus erythematosus (SLE) (25%
of investigated sera) and mixed connective tissue disease
sera [11,12].
Anticalpastatin
Calpains are calcium-ion-dependent neutral cysteine pro-
teinases. Two forms of calpains exist: µ-calpains (calpain I,
which needs micromolar concentrations of Ca2+ for activ-
ity) and m-calpains (which require millimolar amounts of
Ca2+ for activity). Substrates of these enzymes are highly
diverse and include cytoskeletal proteins, nuclear proteins,
cytokines and extracellular matrix proteins including pro-
teoglycans [13]. Elevated levels of extracellular calpain in
the inflamed synovium have been reported, which suggests
that calpains might be secreted by synovial cells and could
play a role in cartilage degradation in RA [14,15].
Calpastatin is the natural inhibitor of calpains. Using
immunoblots of recombinant protein, autoantibodies
directed to calpastatin can be found in about 45% of the
RA sera, but also sera from SLE, myositis and systemic
sclerosis contain antibodies directed to calpastatin
[16,17]. A recent study using recombinant fusion proteins
with truncated forms of calpastatin showed that anti-
calpastatin antibodies can also be found in sera from
healthy individuals, even in comparable numbers, relative
to RA patients [18]. Autoantibodies directed to calpastatin
could increase calpain activity, leading to enhanced carti-
lage damage, and could therefore contribute to the sever-
ity of the disease [14].
Other RA-associated autoantibodies
RA patients produce autoantibodies directed to many
autoantigens, but most of them are not specific for RA.
Among these nonspecific antibodies are those directed
to a wide variety of cartilage proteins such as collagen
and fibronectin, but also antiphospholipid antibodies and
antineutrophil cytoplasmic antibodies (ANCA) can often
be found.
Although autoantibodies against several types of colla-
gens have been described, the autoimmune reactiondirected to collagen type II (anti-CII) seems predominant.
Anticollagen antibodies are present in about 30% of RA
patients and only in HLA-DR4-positive ones [19].
Although anti-CII autoantibodies can be found in serum of
only a small proportion of the RA patients, these antibod-
ies and anti-CII-producing B cells are present in the joints
of the majority of these patients [20]. It is not clear
whether the occurrence of anticollagen autoantibodies
plays a role in the pathogenesis of RA or is merely a result
of the disease [3,19]. Anticollagen autoantibodies show a
low specificity and can also be found in other auto-
immune disorders (e.g. SLE, 20% occurrence; systemic
sclerosis, 15% occurrence; relapsing polychondritis, 50%
occurrence) and infectious diseases (e.g. leprosy, 50%
occurrence). Anti-CII IgG titers in serum and synovial fluid
appear to directly correlate with levels of acute-phase
reactants, and of cytokines such as tumor necrosis factor-
α and interleukin-6 [21]. A possible explanation for these
findings is cross-reactivity with the first complement com-
ponent, C1q, which has a collagen-like tail [22].
Fibronectin is a dimeric glycoprotein that interacts with col-
lagens, fibrin(ogen), heparin and various cell surface adhe-
sion molecules. It is present in connective tissue matrices
and on the surface of epithelial cells. The protein is also (in
a soluble form) present in plasma and other body fluids.
Autoantibodies to fibronectin are found in about 14% of
RA patients and show a low specificity (SLE, 34%) [23].
ANCA were initially discovered in serum of RA patients by
immunofluorescence on neutrophilic granulocytes and can
be subdivided into two groups depending on their localiza-
tion: cytoplasmic ANCA, and perinuclear ANCA (reviewed
in [24]). ANCA can be found in up to one-third of the RA
patients, but can also be detected in other autoimmune
conditions and various infectious diseases [25–27].
Autoantibodies directed to the nonhistone chromosomal
proteins HMG1 and HMG2 can be detected in about
25–40% of the RA patients, but similar frequencies have
also been reported for SLE, Sjögren’s syndrome and
scleroderma patients (see references in [28]).
Antiphospholipid antibodies, like autoantibodies directed
to cardiolipin, are not only found in autoimmune diseases
such as RA (4–49% occurrence) and SLE (~40% occur-
rence), but are also present in many infectious diseases
(e.g. syphilis, 75% occurrence; leprosy, 67% occurrence).
The incidence in RA can vary strongly, depending on the
methodology of detection and the selection of patients
(reviewed in [29]).
Autoantibodies specific for RA
Sa protein
The antigen Sa is recognized by autoantibodies in about
40% of the RA sera with a rather high specificity [30,31].
These antibodies can already be detected at an early
stage of the disease, albeit with a rather low sensitivity
(23%) [30,32]. The antigen is a 48–50 kDa protein, pre-
dominantly present in human placenta extracts [31]. It can
also be detected in human spleen and RA pannus tissue,
but not in cultured cells. As explained by Menard et al.
[33], Sa possibly is a citrullinated form of the intermediate
filament protein vimentin (in cultured cells, vimentin is nor-
mally not citrullinated). Other workers have postulated that
part of the Sa activity could be identical to human
α-enolase [34]. If the Sa protein indeed is citrullinated, the
antigen can be categorized in the filaggrin/cyclic citrulli-
nated peptide (CCP) family of citrullinated auto-antigens
(see below).
Heavy chain binding protein (p68)
Autoantibodies directed to the p68 protein, recently iden-
tified as heavy chain binding protein (BiP), occur in about
64% of RA patients and appear to be highly specific for
the disease [35–37]. The reported specificity of these
antibodies still awaits further confirmation by clinical
studies. The BiP antigen is also a target of RA-specific
T-cell and B-cell immune responses [38], and is over-
expressed in RA synovial tissue compared with control
tissue. BiP is a ubiquitously expressed chaperone protein
predominantly localized in the endoplasmic reticulum. The
major B-cell epitope of this antigen appears to be a
N-acetylglucosamine carbohydrate group, which is possi-
bly important for its cellular localization [39]. The BiP
protein can be detected in the cytoplasm and endoplas-
mic reticulum of cultured cells, but also in low abundance
at the cell surface. Under stress (especially heat shock)
conditions, the antigen can relocalize to the nucleus [39].
This nonphysiological localization of the antigen, accom-
panied by a shift in its glycosylation pattern, might trigger
antigenicity of BiP during the pathogenesis of RA. Anti-
BiP antibodies can also be detected in mice with estab-
lished collagen-induced or pristane-induced arthritis [37].
Glucose-6-phosphate isomerase
The household enzyme glucose-6-phosphate isomerase
(GPI) was recently described as a novel autoantigen in RA
[40]. The antibodies could be detected in 64% of RA
patients but not in controls. Interestingly, anti-GPI antibod-
ies are also present in T-cell receptor-transgenic mice. In
this mouse model system, GPI can serve as an autoantigen
for both B and T cells, and passive transfer of anti-GPI to
normal healthy animals induces arthritis. The anti-GPI anti-
bodies in humans appear to be produced locally, since
anti-GPI titers were higher in RA synovial fluids as com-
pared with RA sera. Immunohistochemistry of synovia from
RA patients showed high concentrations of GPI on the
surface of the synovial lining and on the endothelial cell
surface of arterioles [40]. It is intriguing and significant that
the same autoantigen is targeted by autoantibodies in RA
patients and in a mouse model of RA.
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antifilaggrin/anti-CCP
In 1964 a highly specific RA antibody system directed to a
protein component present in the keratohyaline granules
in the cytoplasm of differentiating buccal mucosa cells
was described. The antigen was referred to as perinuclear
factor, and the antibody activity became known as anti-
perinuclear factor (APF) [41]. APF antibodies combined a
relative high sensitivity (depending on the cohort of
patients being studied, they were present in 49–91% of
RA patients) with a strong specificity (73–99%, reviewed
in [42]). The APF test never became popular because of
several practical inconveniences. Only a few percent of an
average (laboratory) population can donate buccal
mucosa cells differentiated far enough to contain the peri-
nuclear factor. Another inconvenience is the fact that the
antibody activity can only be measured by indirect
immunofluorescence, making interpretation of test results
sometimes very difficult [42].
A related group of RA-specific autoantibodies, the so-
called antikeratine antibodies (AKA), was first described in
1979 [43]. These antibodies stain keratin-like structures in
the cornified layer of esophagus cryostat sections but do
not recognize cytokeratins, as is suggested by the name.
AKA can be detected by indirect immunofluorescence in
36–59% of RA sera with a specificity of 88–99%
(reviewed in [42]). Several studies have shown that the
APF and AKA antibodies target the same antigen, the
epithelial protein filaggrin (for references see [44]).
Filaggrin (filament aggregating protein) is involved in the
organization of cytoskeletal structures in epithelial cells
and is synthesized as a large, heavily phosphorylated pre-
cursor protein, profilaggrin. During differentiation of
epithelial cells, profilaggrin is partly dephosphorylated and
proteolytically cleaved into 10–12 filaggrin subunits.
Finally, about 20% of the arginine residues are enzymati-
cally deiminated to citrulline residues [45]. Conversion of
the basic amino acid arginine into the neutral residue
citrulline is catalyzed by the enzyme peptidylarginine de-
iminase (Fig. 1). It is this modification that has been shown
to be essential for the autoantigenicity of filaggrin [46,47].
Immunoblotting assays and an enzyme-linked immunosor-
bent assay (ELISA) using filaggrin purified from human
skin as an antigen have been developed for the detection
of antifilaggrin antibodies (AFA). Vincent et al. [48] could
detect AFA in 41% of RA sera with 99% specificity. When
combining the AFA immunoblot assay with AKA testing, a
much higher sensitivity (64%), without loss of specificity,
could be achieved [48]. However, the sensitivity of the
assay appears to be dependent on the method for purifi-
cation of the filaggrin. Slack et al. calculated sensitivities
of 12 and 16% for two different filaggrin preparations,
while only one of five positive sera reacted with both
preparations [49]. The AFA-ELISA is somewhat more sen-
sitive (47–54%) than the immunoblot assay [50,51], but
the results are in good agreement with APF data obtained
with the same set of sera [52]. Using in vitro deiminated
recombinant filaggrin, Nogueira et al. [53] could detect
AFA in about 52% of RA sera. The differences in AFA,
APF and AKA results and the influence of the antigen
preparation imply that several (rather than one single) epi-
topes are recognized.
The AFA-ELISA test detected 45% of RF-negative erosive
cases, in particular those with larger numbers of erosive
joints. Testing for AFA could therefore supplement RF in
the prediction of erosive disease. The test could also be
helpful in the diagnosis of RA in those cases that do not
completely fulfill the 1987 American College of Rheumatol-
ogy criteria [52]. In a case–control study, pre-illness AFA
titers were found to directly be related to the risk of devel-
oping RF-positive RA, but not RF-negative arthritis [54].
AFA are present early in the disease, as is the case with
APF and anti-CCP antibodies (see below), and raised AFA
levels correlate with the severity of the disease. However,
there is discussion whether disease activity and radiologi-
cal damage can be predicted by AFA levels [51,52,55].
One disadvantage of the AFA test is the difficulty of
obtaining an antigen preparation that is pure and contains
a reproducible citrulline content. These problems do not
occur when citrullinated peptides are used as the antigen,
as has been shown by Schellekens et al. [46]. RA sera,
however, show different patterns of reactivity with the cit-
rullinated peptide variants, which emphasizes the hetero-
geneous nature of the autoimmune response. With a
combination of nine citrullinated peptide variants, a sensi-
tivity of 76% could be reached with a specificity of 96%
[46]. The test could be improved and simplified using a
single cyclic peptide that has a three-dimensional struc-
ture optimally recognized by the heterogeneous popula-
tion of RA autoantibodies [56]. Recent studies indicate
that this anti-CCP test (manufactured by Euro-Diagnostica
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Figure 1
The enzymatic conversion of peptidyl-arginine to peptidyl-citrulline.BV, Arnheim, The Netherlands) is extremely specific
(~98%) and has a reasonable sensitivity of 68–75%
[57,58] (van Boekel and de Jong, unpublished observa-
tions, 2001). Anti-CCP antibodies can be detected very
early in RA, although with a somewhat lower sensitivity
(40–60%) [32,57–60]. Anti-CCP appears to be a good
prognostic marker and has a high discriminating power
between erosive and nonerosive RA [61]. RA patients
positive for anti-CCP develop significantly more radiologi-
cal damage than anti-CCP-negative patients [59,60],
although anti-CCP combined with RF appears to be an
even better prognostic marker [56,58,61].
The results described (supported by the fact that non-
filaggrin-like citrulline-containing antigens are also recog-
nized by RA sera [62]) suggest that, in principle, most
citrullinated proteins/peptides will be recognized by auto-
antibodies in RA sera, all be it with different sensitivities
and specificities. Since filaggrin is not present in the joint,
it is reasonable to assume that other citrulline-containing
proteins are present in the RA synovium. In RA pannus
tissue, AFA are produced by local plasma cells and consti-
tute a higher proportion of IgG than in serum [63]. Further-
more, B cells from the synovial fluid of anti-CCP-positive
RA patients spontaneously produce anti-CCP antibodies,
while peripheral blood B cells or B cells from anti-CCP-
negative RA patients do not [64]. This suggests an
antigen-driven maturation of CCP-specific B cells at the
site of inflammation in RA. One of these possible auto-
antigens, citrullinated fibrin, has recently been identified
[65]. The possible role of citrullinated fibrin and other cit-
rullinated antigens in the pathophysiology of RA remains
to be elucidated [66].
Conclusions and discussion
RA is accompanied by the occurrence of many autoanti-
bodies in the serum of the patient. Most of these antibod-
ies are not specific for RA because they also occur in
other inflammatory conditions. Other antibodies appear to
be more specific and are, in some cases, almost exclu-
sively present in RA.
The possible pathogenic nature of autoantibodies in RA is
still controversial (reviewed in [67]). The evidence for the
pathogenic involvement of RF in RA can, at best, be con-
sidered indirect [67]. There is an association of RF with
the severity of RA, and RF-positive patients can turn RF-
negative following therapy [3,68]. Administration of human
IgG or IgM monoclonal RF to mice (suffering from colla-
gen-induced arthritis) results in an enhanced activity and
severity of the disease and in an increase in anticollagen
antibody levels [69]. RF has the capacity to activate the
complement cascade, which could be an important factor
in the disease activity and the chronic character of RA
[3,70]. RF is also found in healthy individuals, however,
and possibly even plays a physiological role in immune
complex clearance [3].
Anticollagen antibodies possibly have pathogenic poten-
tial. Injection of serum IgG from a RF-negative patient with
high levels of anti-CII antibodies induces a mild form of
inflammatory arthritis in mice [71,72], but the pathogenic
involvement of anti-CII antibodies is much less evident in
human RA. Anticalpastatin antibodies could contribute to
the pathology by inhibiting calpastatin functioning [13].
The participation of other autoantibody systems (such as
anticitrullinated protein, anti-GPI and anti-Sa antibodies) in
RA pathogenesis is still unclear, although their high speci-
ficity adds to the increasing body of evidence that they
may be important in maintaining RA.
Some of the RA-specific antibodies might be very helpful
in the early diagnosis and prognosis of the disease. These
antibodies are presented in Table 1. Most promising for
the future appears to be the growing family of antigens
containing one or more citrulline residues. Some of these
antigens (i.e. filaggrin and CCP) have recently been
applied in simple and easy-to-use ELISA tests, and have
been shown to be very specific for RA, to be able to diag-
nose RA in a very early phase of the disease, and to
predict erosive disease. As such, this class of anticitrulli-
nated protein autoantibodies has the potential to become
the serological marker for RA of the future.
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Table 1
Rheumatoid arthritis autoantigens with relatively high specificity
Antigen Sensitivity (%) Specificity (%)
Rheumatoid factor 70–75 Also present in other autoimmune diseases, 
infectious diseases and healthy individuals
Antiperinuclear factor/antifilaggrin/anticyclic citrullinated peptide 50–91 > 97
Sa ≤ 40 85–95
Heavy chain binding protein (BiP)/p68 ≤ 68 > 97*
Glucose-6-phosphate isomerase ≤ 64 > 95*
*Requires confirmation by further studies.Although we know that the anticitrullinated protein antibod-
ies are locally generated in the inflamed joint, we also know
that both filaggrin and CCP are not present in this tissue. It
was recently shown that fibrin in the pannus tissue is citrul-
linated. This intriguing finding underlines the idea that local
citrullination of extravascular proteins might be one of the
initiating event(s) leading to autoimmunity in RA.
The key question why only patients with RA develop anti-
bodies to citrullinated (synovial) proteins remains to be
answered. Further research will hopefully reveal the signifi-
cance of protein citrullination in the immunopathology of RA.
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